TY - JOUR
T1 - Innovative nanocarrier systems for enhanced delivery of phyto-active compounds in cancer therapy
AU - Dwivedi, Khusbu
AU - Sahoo, Ankit
AU - Almalki, Waleed H.
AU - Almujri, Salem Salman
AU - Aodah, Alhussain
AU - Alruwaili, Nabil K.
AU - Rab, Safia Obaidur
AU - Alanezi, Abdulkareem Ali
AU - Haji, Esraa M.
AU - Barkat, Md Abul
AU - Singh, Tanuja
AU - Rahman, Mahfoozur
N1 - Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Millions of people worldwide suffer from cancer, facing challenges such as treatments affecting healthy cells, suboptimal responses, adverse effects, recurrence risk, drug resistance, and nonspecific targeting. Chemoresistance leads to fatalities, but phytoactives show promise in cancer management despite limitations such as high metabolism, poor absorption, and high dosage requirements. Challenges in the large-scale isolation of phytoactive compounds, solubility, bioavailability, and targeting limit their development. Recent developments, including carbohydrate, lipid, and protein-based nanoparticles, have enhanced cancer treatment by improving the bioavailability and targeted delivery of phytoactives such as polyphenols, alkaloids, sulfur-containing compounds, flavonoids, and terpenes. Despite advancements, clinical application faces hurdles such as poor bioavailability and inconsistent immune responses. This article discusses the promise of phytoactive-loaded nanoformulations in cancer management, highlighting targeted drug delivery, unmet needs, and challenges. Further research is needed to overcome these challenges and fully understand the potential of phytoactives in cancer management.
AB - Millions of people worldwide suffer from cancer, facing challenges such as treatments affecting healthy cells, suboptimal responses, adverse effects, recurrence risk, drug resistance, and nonspecific targeting. Chemoresistance leads to fatalities, but phytoactives show promise in cancer management despite limitations such as high metabolism, poor absorption, and high dosage requirements. Challenges in the large-scale isolation of phytoactive compounds, solubility, bioavailability, and targeting limit their development. Recent developments, including carbohydrate, lipid, and protein-based nanoparticles, have enhanced cancer treatment by improving the bioavailability and targeted delivery of phytoactives such as polyphenols, alkaloids, sulfur-containing compounds, flavonoids, and terpenes. Despite advancements, clinical application faces hurdles such as poor bioavailability and inconsistent immune responses. This article discusses the promise of phytoactive-loaded nanoformulations in cancer management, highlighting targeted drug delivery, unmet needs, and challenges. Further research is needed to overcome these challenges and fully understand the potential of phytoactives in cancer management.
KW - Cancer
KW - chemotherapy
KW - liposomes
KW - phytoactives
KW - preclinical challenges
KW - solid lipid nanoparticles
KW - targeted therapy
KW - unmet need
UR - http://www.scopus.com/inward/record.url?scp=85212507154&partnerID=8YFLogxK
U2 - 10.1080/17435889.2024.2440301
DO - 10.1080/17435889.2024.2440301
M3 - Review article
C2 - 39703154
AN - SCOPUS:85212507154
SN - 1743-5889
VL - 20
SP - 91
EP - 116
JO - Nanomedicine
JF - Nanomedicine
IS - 1
ER -